Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Gracell Biotechnologies

AstraZeneca buys Chinese cancer therapy firm Gracell for $1.2bn

Gracell Biotechnologies acquisition marks China’s growing importance to the Anglo-Swedish drugmaker

The Guardian - UK

Benzinga's Top Ratings Upgrades, Downgrades For September 22, 2022

Benzinga's Top Ratings Upgrades, Downgrades For September 22, 2022

Preview: Gracell Biotechnologies's Earnings

Preview: Gracell Biotechnologies's Earnings

Gracell Biotechnologies (NASDAQ:GRCL) is set to give its latest quarterly earnings report on Monday, 2022-05-16. Here's what investors need to know before the announcement. Analysts estimate that Gracell Biotechnologies will report an earnings per share (EPS) of $-0.21.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Benzinga's Top Ratings Upgrades, Downgrades For April 4, 2022

12 Health Care Stocks Moving In Thursday's Intraday Session

Gracell Biotechnologies Earnings Preview

Gracell Biotechnologies (NASDAQ:GRCL) is set to give its latest quarterly earnings report on Monday, 2022-03-14. Here's what investors need to know before the announcement. Analysts estimate that Gracell Biotechnologies will report an earnings per share (EPS) of $-0.33.

Organisations

B of A Securities

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Topics

inkl

Read news from The Economist, FT, and more,
with one subscription

Places

341,374 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play